Advances in treatment of spinal muscular atrophy–new phenotypes, new challenges, new implications for care

DC Schorling, A Pechmann… - Journal of …, 2020 - content.iospress.com
Abstract Spinal Muscular Atrophy (SMA) is caused by autosomal recessive mutations in
SMN1 and results in the loss of motor neurons and progressive muscle weakness. The …

Emerging therapies and challenges in spinal muscular atrophy

MA Farrar, SB Park, S Vucic, KA Carey… - Annals of …, 2017 - Wiley Online Library
Spinal muscular atrophy (SMA) is a hereditary neurodegenerative disease with severity
ranging from progressive infantile paralysis and premature death (type I) to limited motor …

A multi-source approach to determine SMA incidence and research ready population

IEC Verhaart, A Robertson, R Leary, G McMacken… - Journal of …, 2017 - Springer
In spinal muscular atrophy (SMA), degeneration of motor neurons causes progressive
muscular weakness, which is caused by homozygous deletion of the SMN1 gene. Available …

SMArtCARE-A platform to collect real-life outcome data of patients with spinal muscular atrophy

A Pechmann, K König, G Bernert, K Schachtrup… - Orphanet journal of rare …, 2019 - Springer
Background Survival and quality of life for patients affected by spinal muscular atrophy
(SMA) are thought to have improved over the last decade due to changes in care. In …

Spinal muscular atrophy: an evolving scenario through new perspectives in diagnosis and advances in therapies

I Angilletta, R Ferrante, R Giansante… - International Journal of …, 2023 - mdpi.com
Spinal muscular atrophy (SMA) linked to 5q is a recessive motor neuron disease
characterized by progressive and diffuse weakness and muscular atrophy. SMA is the most …

Disease burden of spinal muscular atrophy in Germany

C Klug, O Schreiber-Katz, S Thiele, E Schorling… - Orphanet Journal of …, 2016 - Springer
Background This study aimed at analyzing the economic burden and disease-specific health-
related quality of life (HRQOL) of patients with spinal muscular atrophy (SMA) in Germany …

Onasemnogene abeparvovec for the treatment of spinal muscular atrophy

HJ McMillan, CM Proud, MA Farrar… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Gene therapy for spinal muscular atrophy (SMA) represents a significant
milestone in the treatment of neurologic diseases. SMA is a neurodegenerative disease that …

Limb-girdle muscular dystrophies—international collaborations for translational research

R Thompson, V Straub - Nature Reviews Neurology, 2016 - nature.com
The limb-girdle muscular dystrophies (LGMDs) are a diverse group of genetic
neuromuscular conditions that usually manifest in the proximal muscles of the hip and …

Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy

CA Wijngaarde, RC Brink, FAS de Kort, M Stam… - Neurology, 2019 - AAN Enterprises
Objective To investigate the natural course of scoliosis and to estimate lifetime probability of
scoliosis surgery in spinal muscular atrophy (SMA). Methods We analyzed cross-sectional …

Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy

A Lusakowska, M Jedrzejowska, A Kaminska… - Orphanet Journal of …, 2021 - Springer
Background Spinal muscular atrophy (SMA) is one of the most frequent and severe genetic
diseases leading to premature death or severe motor disability. New therapies have been …